NCT06490263View on ClinicalTrials.gov

the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human

PHASE1RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

October 19, 2024

Study Completion Date

December 10, 2024

Conditions
Overweight and ObesityHealthy
Interventions
DRUG

Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects

Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.

DRUG

Mulberry Twig Alkaloids Tablets with single dose in healthy subjects

Parts Two: Administered by swallowing after meals with four distinct dosage groups.

DRUG

Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects

Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.

DRUG

Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects

Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.

Trial Locations (1)

100034

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
collaborator

Peking University First Hospital

OTHER

lead

Beijing Wehand-Bio Pharmaceutical Co., Ltd

INDUSTRY